Articles tagged with Glioblastomas
A compound has been identified as effective in killing chemotherapy-resistant glioblastoma-initiating cells (GICs), a major challenge in treating this devastating cancer. The research also showed that the compound is non-toxic to normal cells, raising hopes for developing drugs with low toxicity.
University of Minnesota Medical School researchers have made a breakthrough in combating glioblastoma, the most common form of adult brain cancer. By combining ultrasound with engineered glass particles, they were able to create a 'Goldilocks' balance that awakens the body's immune response and boosts the effectiveness of immunotherapy.
Researchers at the Spanish National Research Council (CSIC) have found that glioblastoma hijacks pericytes to promote tumor progression and evade the immune system. By targeting chaperone-mediated autophagy, they may develop a new therapeutic approach to treat this aggressive brain cancer.
Researchers at the University of Georgia have discovered a new use for an existing insulin compound to treat glioblastoma, a fast-growing and often fatal form of brain cancer. The study found that surfen-treated cells were blocked from tumor growth and the spread of tumor cells in the brain.
Scientists at USC and UC San Diego have discovered a potential novel target for treating glioblastoma, the deadliest form of brain cancer. They found that targeting the circadian clock in tumor stem cells can disrupt the growth and development of the tumor, leading to its death.
Researchers at Cleveland Clinic have identified FGF2 as a novel druggable target for glioblastoma, the most common primary malignant brain tumor. The study reveals that FGF2 is an intermediary in a multi-step pro-cancer signaling loop, suggesting that targeting it may halt the growth and spread of glioblastoma.
Researchers at Texas A&M University have found that the AH receptor can actually block invasion of glioblastoma cells, rather than promoting it. Adding certain ligands to the receptor has been shown to inhibit cell invasion and provide additional protection to the brain.
Researchers at the University of Sussex have identified novel biomarkers in bodily fluids that could signal the presence of glioblastoma. These biomarkers are associated with extracellular vesicles and may enable a simpler way to test for the tumor, rather than a biopsy.
A study published in Acta Neuropathologica Communications found that interregional differences in the somatic genetic landscape of glioblastoma affect prognosis. The research analyzed Japanese patients with IDH-wildtype GBM and discovered a biomarker, triple CNA, associated with survival duration.
A two-step gene therapy treatment has shown promise in treating recurrent glioblastoma by boosting IL-12 production and enhancing antitumor immune cell infiltration. The treatment has also been found to be safe, with serious side effects easily reversible after discontinuing treatment.
A clinical trial found that an oral activator, veledimex, controlled the transcription of human interleukin-12, reducing toxicity while preserving anti-tumor effects. Patients with recurrent glioblastoma had improved overall survival rates, with some experiencing up to 17.8 months of survival.
Researchers found that adding MS drug teriflunomide to targeted cancer therapy significantly shrinks glioblastoma tumors and improves mouse survival. The treatment targets cancer stem cells, which are responsible for tumor recurrence.
A Phase 0 clinical trial shows ribociclib effectively targets glioblastoma cells and breaks the blood-brain barrier, offering a new treatment hope. The study identifies a potential mechanism of drug resistance, paving the way for a combined-drug regimen to overcome resistance.
A study identified Glycerol-3-phosphate dehydrogenase 1 (GPD1) as a molecular marker specific to dormant glioma stem cells. GPD1-producing cells are resistant to chemotherapy and radiation, and their activation leads to tumor relapse.
Researchers found that inhibiting ID1 slows tumour progression in glioblastoma, breast and melanoma. Targeting the protein with medication may present a promising strategy for patients.
A recent study found that only 5.5% of glioblastoma patients survive five years after diagnosis, highlighting the need for more aggressive treatments to improve long-term survival. The research analyzed 48,652 cases and identified factors associated with five-year survival, including age, race, gender, and treatment with radiotherapy.
Research at MD Anderson Cancer Center discovers a symbiotic circuit between PTEN-deficient glioblastoma cells and macrophages, which creates a mutually supportive relationship. Inhibiting LOX, a novel attractor of macrophages, shrinks tumors and blocks macrophage infiltration.
Researchers paired a calorie-restricted ketogenic diet with a tumor-inhibiting antibiotic to destroy cancer stem cells and mesenchymal cells in glioblastoma, a fast-moving brain cancer. The combination killed tumor cells while reversing disease symptoms and improving mouse survival.
Researchers at IRB Barcelona discovered that the antibody mAb806 can be used to treat many types of tumors with EGFR mutations, not just a specific one. The study also found that even non-mutated EGFR can be treated to make it susceptible to mAb806 therapy.
Researchers from FEFU and international partners discover potential targets for glioblastoma multiforme treatment by studying proteins in the WNT signaling pathway. The findings could lead to improved antitumor therapy outcome through suppression of cancer stem cells, accelerating tumor growth rate.
Researchers discovered multiple potential targets for glioblastoma by systematically profiling patient-derived brain tumour cells. They found that adult glioblastoma cells rely on genes important for brain development in infancy, highlighting the need for new research to understand the developing human brain.
Scientists identified a molecular driver of glioblastoma, a highly aggressive and treatment-resistant brain cancer, by analyzing cell-by-cell genetic data. Researchers found that reprogramming primitive oligodendrocyte progenitors into stem-like cells plays a key role in glioma initiation and progression.
A new experimental glioblastoma vaccine developed by Jefferson and Imvax has shown promising results in a phase Ib clinical trial. The treatment was found to slow tumor recurrence and prolong patient survival in patients with newly diagnosed glioblastoma multiforme.
Researchers identified three key genetic drivers of glioblastoma development, including the activation of telomerase. Early tumors exhibit concurrent genetic alterations, but recurrent tumors display distinct mutation patterns. This study highlights the need for new treatments to effectively target resistant subclones.
A team of researchers discovered a way to make glioblastoma brain tumors more sensitive to radiation by blocking the activity of a specific protein, PTEN. This breakthrough could lead to improved treatment prospects for patients with this aggressive form of brain cancer.
Researchers at the University of Bonn have reported significant progress in treating aggressive brain tumors like glioblastoma. Combination chemotherapy with CCNU and temozolomide significantly prolongs patients' survival time, with a notable benefit for those with methylated MGMT promoter.
Research reveals that patients with specific MAPK mutations are more likely to respond to immunotherapy drugs in glioblastoma. The study also found that tumors with PTEN mutations were less responsive to treatment, suggesting new targets for treatment development.
A multidisciplinary team of researchers has developed a human induced pluripotent stem cell (IPSC) derived 3D organoid model for drug testing. The system demonstrated anti-tumor efficacy with doxorubicin and predicted clinical response to temozolomide, offering a more personalized approach to treating glioblastoma.
A study by MGH researchers reveals that brain tumors use existing blood vessels to resist anti-angiogenic drugs, leading to compression and stimulation of angiogenesis. The study suggests targeting vessel co-option before using anti-angiogenic drugs could be an effective strategy for glioblastoma treatment.
A new method of using multiple microRNAs to weaken cancer cells has shown promising results in preclinical models, increasing survival in a murine model of glioblastoma by five-fold when combined with chemotherapy. The treatment strategy weakens tumor cells but does not directly kill them, making it an advantage for further treatment.
Researchers at MD Anderson Cancer Center have discovered a link between FGL2 protein and glioblastoma progression. FGL2, known for suppressing the immune system, is highly expressed in GBM and can be eliminated by knocking it out, eliminating tumor progression in mice with intact immune systems.
A recent study has found that standard treatment for glioblastoma is more effective in women than men, with tumor growth velocity showing a steady decline after treatment. The researchers identified distinct molecular signatures of the disease in men and women, which could lead to sex-specific treatment strategies.
Researchers at McGill University Health Centre found a gene called EGFRvIII that changes the content of messages exchanged between cells, leading to aggressive brain cancer glioblastoma. This discovery holds promise for developing tests and tailored treatments for patients with glioblastoma.
A team of University of Arizona researchers discovered a protein called WIF-1 that might increase survival in glioblastoma patients. Long-term survivors rely on genes that suppress the Wnt signaling pathway, which fuels tumor growth. The study aims to create a drug targeting this pathway for more precise treatment.
Researchers at Virginia Tech have discovered a drug that can block the spread of glioblastoma, the deadliest form of brain cancer, by halting the rapid movement of fluid within the body. The breakthrough finding could lead to improved treatment options for patients with glioblastoma.
Researchers have developed a new tool to study genetic switches in glioblastoma tumors, which drive cancer growth and survival. The new technique uses ChRO-seq data to classify tumors into subtypes based on active switches, with potential applications in predicting patient outcomes and developing new therapies.
A nationwide Finnish study found that brain cancer survival has improved overall, with younger patients experiencing significant gains in median survival time. However, elderly patients saw minimal improvement, highlighting the need for more effective treatment strategies for this growing patient population.
Researchers at Barrow Neurological Institute have developed a new clinical trial regimen for treating glioblastoma, a complex brain tumor. The study demonstrates the ability of the drug AZD1775 to penetrate brain tissue and provide clinically-relevant activity against human glioblastoma.
Researchers at UTMB successfully adapted a Zika virus vaccine to target and kill glioblastoma, the deadliest form of brain tumor. The altered vaccine effectively destroyed cancerous brain cells in mice without harming healthy ones.
Researchers have successfully deployed a Zika virus vaccine to target and kill human glioblastoma brain cancer stem cells in mice, offering a potential new treatment option. The vaccine demonstrated effectiveness in delaying tumor development and prolonging survival time in mouse models.
Scientists at Virginia Tech Carilion Research Institute have identified a potential strategy in fighting brain cancer by targeting a gene associated with circadian rhythms. Inhibiting this gene may inhibit cancer stem cells from renewing themselves and differentiating into glioblastoma cells.
The Ben and Catherine Ivy Foundation has partnered with Barrow Neurological Institute to fund a $50 million effort to accelerate drug discovery and clinical testing for glioblastoma. The new Ivy Brain Tumor Center aims to provide individualized experimental therapies to malignant brain tumor patients worldwide.
Researchers identified epigenetic changes that accompany glioblastoma progression and predict patient survival. DNA methylation sequencing can be used to predict clinically relevant tumor properties.
MIT researchers develop a machine-learning model that reduces toxic chemotherapy and radiotherapy dosing for glioblastoma patients, maintaining tumor-shrinking potential while minimizing side effects. The model uses reinforced learning to favor lower doses and schedules, improving patient quality of life.
A KAIST research team identified where glioblastoma mutation drivers originate, revealing that normal SVZ tissue away from the tumor contains low-level mutations. The study suggests novel ways to treat glioblastoma and implies a new paradigm for therapeutic strategies.
Scientists have found that internal mammary chain irradiation and anthracycline-based chemotherapy increase cardiovascular disease risks, while a new test may detect colorectal cancer in primary care. Researchers also discovered circulating tumor cell clusters in human glioblastoma, suggesting a new target for treatment
A study published in PLOS ONE found that different mutations in the PIK3CA gene drive glioblastoma growth, but not a single targeted drug. However, combination therapies show promise, particularly with buparlisib and selumetinib.
A study published in Cancer Cell found a rare EGFR mutation, A289D/T/V, driving more aggressive brain tumors with poorer survival rates. Researchers discovered that targeting this mutation with the monoclonal antibody drug mAb806 may reduce tumor growth and extend lives.
Researchers have found that the EGFR A289 mutation in glioblastoma multiforme tumors is susceptible to the Ludwig-developed antibody drug mAb806, which has shown promising results in clinical trials. The study suggests that this broader class of brain cancers may be targeted by the antibody drug.
The California Institute for Regenerative Medicine (CIRM) has awarded City of Hope $3.7 million to develop a phase 1 clinical trial for glioblastoma patients that will genetically engineer their stem cells to better tolerate chemotherapy's side effects, allowing them to receive higher doses of the therapy. The trial is expected to star...
A new study found that an experimental drug called AZ32 selectively sensitizes brain tumors to radiation, extending the survival of mouse models with human glioblastoma multiforme. The combination therapy forced GBM cells to undergo mitotic catastrophe, leading to cell death.
A recent study reveals that dying glioblastoma cells can communicate with remaining tumor cells through extracellular vesicles, increasing aggressiveness and therapy resistance. This mechanism may provide a new target for novel cancer therapies to treat glioblastoma and potentially other cancer types.
A study led by Diogo Castro discovered a genetic programme that controls the invasiveness of glioblastoma tumors. The researchers found that Zeb1, a previously known molecule involved in glioblastoma invasiveness, plays a crucial role in enabling cancer cells to invade surrounding brain tissue.
A new atlas maps out comprehensive information on glioblastoma at the cellular and molecular levels, aiming to improve diagnosis and treatment. The atlas, created by an international team led by Jill S. Barnholtz-Sloan, provides a road map of different cells and potential molecular changes in glioblastoma tumors.
A quartet of NFCR scientists publishes papers on possible bases for brain cancer treatments and insight into somatic mutations, advancing understanding of glioblastoma multiforme and its resistance to anti-angiogenesis drugs. The findings also identify a potential therapeutic strategy using MDA-9/Syntenin.
Salk Institute researchers have generated aggressive glioblastoma multiforme tumors in human cerebral organoids using CRISPR-Cas9 tool. The new model could be used to study tumor progression, investigate new drugs or personalize treatments for patients.
A new study found that some types of glioblastoma tumors shed extracellular vesicles containing PDL-1, which helps them evade the immune system. The presence of PDL-1 DNA in blood samples from patients with glioblastoma may serve as a biomarker for the disease.
A new microfluidic device developed by Massachusetts General Hospital may help monitor a tumor's response to therapy and provide detailed information to guide treatment choice. The device isolated tumor-specific EVs from all 13 patients with glioblastoma multiforme, identifying key genetic and molecular information.
A phase I clinical trial found that the altered adenovirus DNX-2401 allowed 20 percent of patients with recurrent glioblastoma to live for three years or longer. The virus triggered an immune response, leading to tumor reduction and complete responses in some patients.
A Clemson University undergraduate researcher has identified 22 genes associated with aggressive brain cancer glioblastoma. The discovery was made using a novel computer software that analyzed genomic data from two online public databases, revealing co-expression relationships between the genes.